Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Pharmaceutical Journal of Indonesia Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Folia Medica Indonesiana
Muzayyanah, Binti
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Analysis of Prophylactic Antibiotics Usage in Caesarean Section Delivery Muzayyanah, Binti; Yulistiani, Yulistiani; Hasmono, Didik; Wisudani, Nuraida
Folia Medica Indonesiana Vol. 54, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Caesarean section is the delivery through a surgical incision in the abdomen and uterus with various risks, such as Surgical Site Infection (SSI) which either occurs rapidly (24-48 hours postoperatively) or delayed. To reduce the risk of various post-cesarean section infections, prophylactic antibiotics are given. The administration of prophylactic antibiotics with recommended regimens, such as in developed countries as in the United States and Europe, with first generation of cephalosporins has not been applied in Dr. Iskak Hospital, Tulungagung. This hospital still used other types of antibiotics, such as cefotaxime or ceftriaxone. In addition, for several reasons, prophylactic antibiotics were continued with other antibiotics to reduce the risk of delayed infection. This study was designed to analyze the effectiveness of prophylactic antibiotics as recommended in cesarean section. This was a prospective observational study with consecutive sampling type, examined 41 mothers with cesarean section at the Department of Obstretics and Gynecology, Dr. Iskak Hospital, Tulungagung, Indonesia. This study was conducted from May to July, 2017. The results of the study showed that the effectiveness of prophylactic antibiotic use was 98% based on the clinical parameters and maternal laboratory outcome, which showed that SIRS was in normal category. Whereas, there was one mother (2%) who had SSI on day 10 postoperatively.
Cost-Effectiveness Analysis of Insulin Therapy in Patients with Type 2 Diabetes Mellitus (The research was conducted at dr. Iskak Tulungagung Hospital) Putri, Nadhifa Maharani Mega Mulya; Hidayati, Ika Ratna; Atmadani, Rizka Novia; Muzayyanah, Binti
Pharmaceutical Journal of Indonesia Vol. 11 No. 2 (2026)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/

Abstract

Introduction: Diabetes mellitus is a series of metabolic diseases with signs of hyperglycemia arising from problems with insulin secretion or both. The cost of treating diabetes mellitus was estimated at USD 727 billion in 2017 and is expected to increase every year. The variation in antidiabetic drugs will lead to variation in cost and success rate. Objectives: Therefore, cost-effectiveness analysis, also known as method rate analysis, is used to determine the method that has the lowest cost and is effective to achieve the same goal. Objectives: The purpose of this study was to determine the cost-effectiveness of insulin therapy in patients with type 2 diabetes mellitus hospitalized at RSUD dr. Iskak Tulungagung Regency in 2023. Methods: The method used was a descriptive non-experimental approach, with a cross-sectional design and the instrument used was a retrospective data collection sheet at RSUD dr. Iskak Tulungagung Regency totaling 74 patients. Results: The results and conclusions of this study are the use of Single Insulin with GDS and GDP parameters that have low costs (cost-effective) is Insulin Novorapid® (Insulin Aspart) with an ACER value of Rp. 283,899.23 and the average direct medical costs incurred are Rp. 14,194. 961.25, while the use of combined insulin with RPG, 2-h PG and FPG parameters that have low costs (cost-effective) is the combination of Novorapid® (Insulin Aspart) + Levemir® (Insulin Detemir) with an ACER value of Rp. 412,230.56 and the average direct medical costs incurred are Rp. 18,177,082.66. Conclusions: Novorapid® as single insulin and Novorapid® + Levemir® as combination insulin are cost-effective.
Cost-Effectiveness Analysis of Insulin Therapy in Patients with Type 2 Diabetes Mellitus (The research was conducted at dr. Iskak Tulungagung Hospital) Putri, Nadhifa Maharani Mega Mulya; Hidayati, Ika Ratna; Atmadani, Rizka Novia; Muzayyanah, Binti
Pharmaceutical Journal of Indonesia Vol. 11 No. 2 (2026)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/

Abstract

Introduction: Diabetes mellitus is a series of metabolic diseases with signs of hyperglycemia arising from problems with insulin secretion or both. The cost of treating diabetes mellitus was estimated at USD 727 billion in 2017 and is expected to increase every year. The variation in antidiabetic drugs will lead to variation in cost and success rate. Objectives: Therefore, cost-effectiveness analysis, also known as method rate analysis, is used to determine the method that has the lowest cost and is effective to achieve the same goal. Objectives: The purpose of this study was to determine the cost-effectiveness of insulin therapy in patients with type 2 diabetes mellitus hospitalized at RSUD dr. Iskak Tulungagung Regency in 2023. Methods: The method used was a descriptive non-experimental approach, with a cross-sectional design and the instrument used was a retrospective data collection sheet at RSUD dr. Iskak Tulungagung Regency totaling 74 patients. Results: The results and conclusions of this study are the use of Single Insulin with GDS and GDP parameters that have low costs (cost-effective) is Insulin Novorapid® (Insulin Aspart) with an ACER value of Rp. 283,899.23 and the average direct medical costs incurred are Rp. 14,194. 961.25, while the use of combined insulin with RPG, 2-h PG and FPG parameters that have low costs (cost-effective) is the combination of Novorapid® (Insulin Aspart) + Levemir® (Insulin Detemir) with an ACER value of Rp. 412,230.56 and the average direct medical costs incurred are Rp. 18,177,082.66. Conclusions: Novorapid® as single insulin and Novorapid® + Levemir® as combination insulin are cost-effective.
Co-Authors Didik Hasmono Ika Ratna Hidayati Putri, Nadhifa Maharani Mega Mulya Rizka Novia Atmadani Wisudani, Nuraida Yulistiani Yulistiani, Yulistiani